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Summary Six patients with a total of 34 assessible subcutaneous or cutaneous lesions were treated with
photodynamic therapy using 1.0, 1.5 or 2.0mgkg-I of photofrin II and 25-OOJCcm-2 of red light (630nm).
The incidence of complete tumour response and skin necrosis were used to try to assess the therapeutic ratio
of photodynamic therapy. The tumour response rate was 47%. The rate of tumour control and necrosis
increased in parallel with dose of photosensitizer and light used, implying a low therapeutic ratio. However,
the use of necrosis with eschar formation as an end-point for severe normal tissue damage is questioned as
the skin healed completely in all cases and with minimal discomfort to the patients.
Photodynamic therapy, the use of photosensitizers activated
by light, has been used in man to treat superficial
malignancy for some years (Dougherty et al., 1978;
Dougherty, 1984; Carruth & McKenzie, 1985). Selective
retention of porphyrin in malignant tissue produces a
relatively higher concentration of drug in the tumour than in
the surrounding normal tissue (Gomer & Dougherty, 1979;
Lipson et al., 1961). This difference in concentration of
porphyrin between normal and malignant tissue is the
theoretical basis for the therapeutic ratio of photodynamic
therapy. It is suggested that 3 days is left between giving the
photosensitizer and irradiating the tumour to maximize the
concentration difference (Dougherty et al., 1979).
Previous studies have shown complete response rates of
50-80% (Dougherty, 1984) when photodynamic therapy is
used to treat superficial tumours. This study examines how
tumour response varies with dose of photofrin II
(dihaematoporphyrin ether) and light (630nm) and also tries
to determine the doses of drug and light which will give
maximum tumour response with minimum damage to
normal skin within the irradiated area. This was done by
examining the incidence of complete tumour regression and
of skin necrosis within the irradiated area in cutaneous and
subcutaneous tumours treated with photodynamic therapy.
Patients and methods
Between June and December 1986, six patients with a total
of 34 assessible cutaneous or subcutaneous metastatic or
locally recurrent tumours which were clinically < 1.5cm
thick were treated with photodynamic therapy. At five of
these sites the skin was already ulcerated.
Histology included squamous carcinoma (oral mucosa
primary), small cell lung cancer, large cell anaplastic
carcinoma, malignant melanoma, anaplastic parotid
carcinoma and adenocarcinoma (breast primary).
Patients were given 1, 1.5 or 2mgkg-' body weight of
photofrin II (Photofrin Medical Co. Inc., Raritan, New
Jersey) intravenously. Forty-eight to seventy-two hours later
the lesions were irradiated with red light (630nm) from an
argon-dye laster. The light from the laser was focused into a
600 im optical fibre. The fibre passed through a 'mode
scrambler' to flatten the light beam. The distal end of the
fibre was positioned at an appropriate distance above the
skin surface, so that divergence of the light beam gave the
required size of treatment field.
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The tumours were treated with a 1 cm margin of
surrounding normal skin and the diameter of the treated
areas varied from 2.5 to 6cm. The total doses of light given
at the skin surface were 25, 50, 75 or 100Jcm-2. Light and
drug doses were chosen so that different sized tumours were
spread evenly throughout the treatment groups. The light
was delivered at a dose rate of 40-172mWCcm-2, depending
on the output of the laser and the size of treatment field.
After treatment patients were reviewed weekly for 4 weeks
and monthly thereafter. Complete clinical resolution of the
lesion was used to assess tumour response and the incidence
of damage to skin within the irradiated area was recorded
using skin necrosis and formation of a black eschar as the
end-point.
Results
Within hours of treatment there was blanching within the
irradiated area with an annulus of erythema around the
treated zone. By one week there was intradermal
haemorrhage in the centre of the treatment area. By two
weeks (Figure 1), there was breakdown of the skin with a
black scab or eschar overlying it. Over the next 4-12 weeks
the skin healed from the edges of the necrosed zone. The
only abnormalities visible after healing were a small central
depressed scar and slight pigmentation which gradually
faded (Figure 2).
The overall complete tumour response rate was 47%. If
only the 19 lesions treated with 1.5 or 2mgkg-1 of
photofrin II and 50 or 75Jcm-2 of light are considered the
complete response rate was 74%. Table I shows the increase
of tumour control with increasing dose of photofrin II and
light. Complete tumour response occurred within three weeks
of treatment and persisted during the period of follow-up
(3-5 months). Several sites showed partial regression of the
lesion but tumour regrowth always began again within two
months.
The incidence of skin necrosis also increased with dose of
photofrin II (Table II), in a similar way to tumour response.
The skin necrosis healed completely, with no scarring or
contraction, in all cases but at some sites this took 12 weeks.
Skin necrosis was painless except at one site which caused
some discomfort which lasted for 3 weeks and was relieved
by co-proxamol.
The size of the eschar was dependent on the size of the
treatment field, the diameter of the eschar was 51 + 11%
(mean+ 1 s.d.) of the diameter of the total area illuminated.
Although attempts were made to ensure a flat beam,
differences between size of eschar and size of field
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Table I Number of sites showing complete tumour response
expressed as a fraction of the number of sites receiving the same
dose of photofrin II and light
Dose of light
JCm-2
25
50
75
100
.,MNS
Figure 1 Typical appearance of skin necrosis, with formation of
an eschar, two weeks after photodynamic therapy.
Dose ofphotofrin II
J.Omgkg-1 1.5mgkg-' 2.Omgkg-
0/2
0/2
0/3
0/1
1/6
6/10
4/4
1/1
2/3
2/2
Table II Number of sites showing eschar formation expressed as a
fraction of the number of sites receiving the same dose of photofrin
II and light
Dose of light
JCm-2
25
50
75
100
1.Omgkg-
0/2
0/2
0/3
0/1
Dose ofphotofrin II
1 J.Smgkg-
0/6
7/10
3/4
2.0mgkg-
0/1
3/3
2/2
Figure 2 Appearance of the skin after healing of the skin
necrosis showing pigmentation and a small central depressed
scar.
illuminated could still have been due to a higher light flux in
the centre of the beam. There was a trend for the size of the
eschar to increase with increasing doses of light and drug
(Figure 3). It was, also, our impression that the larger the
eschar the longer the skin took to heal. Even the largest
treated field which was a circle of 6cm diameter healed
within 12 weeks.
Discussion
The complete tumour response rate was comparable to that
observed by other authors (Dougherty, 1984). Dougherty,
also, commented that skin necrosis was common with higher
doses of drug and light. The precise relationship between
treatment parameters, tumour control and skin necrosis is
difficult to discern from previous studies.
The data suggest a low therapeutic ratio for photodynamic
therapy of superficial lesions when early damage to overlying
skin is considered. The dose response curves produced for
varying doses of photofrin II (Figure 4) and light (Figure 5)
show that the incidence of tumour control is almost
paralleled by that of skin necrosis. The use. of skin necrosis
and eschar formation as an end-point for skin damage
within the irradiated area may not be appropriate, however,
it produced minimal discomfort to the patients and in all
cases the lesions healed completely and left a good cosmetic
result. Also, skin damage was transient while tumour control
persisted for the duration of follow-up.
The incidence of skin necrosis and probably the size of the
eschar it produces are dependant on the doses of drug and
light used. If the clinical impression that the larger the eschar
the longer it takes to heal is correct, then increasing the
doses of drug and light will produce not only higher chance
of eschar formation but also these will take a longer time to
heal.
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Figure 3 Variation in diameter of eschar expressed as a
percentage of the diameter of the treatment field (percent eschar)
with dose of light and photofrin II (0 1.5mgkg-' photofrin II,
O 2.Omgkg-1 photofrin II).
The mechanism of production and repair of this skin
damage is interesting because the initial damage appears
severe but it causes minimal pain and always heals without
scarring. The damage does not resemble a thermal burn as
one would expect a full thickness burn to heal with fibrosis
but a partial thickness burn which may heal without scarring
or contacture is usually very painful. Barr et al. (1987) have
shown that in animal mucosa thermal burns produced by
lasers heal by fibrosis whilst damage due to photodynamic
therapy repairs leaving a relatively normal mucosa. The
damage is also different from radiation necrosis as necrosis
such as this usually fails to heal in the long term. Possibly,
these differences are explained by the mode of action of
photodynamic therapy which is postulated to be through
causing vasoconstriction rather than by directly causing cell
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Figure 4 Relationship between incidence of complete tumour
response and skin necrosis and dose of photofrin II (complete
tumour response ~, skin necrosis ---).
The dose of light decreases exponentially with increasing
depth of tissue (Wan et al., 1981). The tumour, in
subcutaneous lesions lies below the skin and will therefore
receive a lower dose of light than the skin but the tumour
showed persistent damage whilst that to the skin was
transient. This implies that the tumour is more sensitive to
photodynamic therapy than normal skin, possibly due to the
greater concentration of photofrin II in the tumour than the
normal surrounding tissue. Whatever the mechanism of this
difference, it is the basis for a relatively good therapeutic
ratio, especially if early skin damage could be prevented.
One possible way of overcoming this is to use optical
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Figure 5 Relationship between incidence of complete tumour
response and skin necrosis and dose of light (complete tumour
response , skin necrosis ---).
fibres implanted in the tumour to deliver light. This should
increase the dose of light given to the tumour relative to the
dose of light delivered to the normal surrounding tissue and
it may also allow treatment of more deep seated tumours.
We conclude that photodynamic therapy is effective in
treating superficial tumours and that refinement of light
delivery systems may further reduce the side-effects of this
relatively non-toxic treatment.
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